AUROPHARMA

expects its China plant to break-even by Q3-Q4 FY26, with the facility ramping up to 2 billion capacity thanks to European and local product approvals. The company remains confident in achieving its internal EBITDA margin target of 20-21% for FY26, driven by factors like Pen-G facility ramp-up, biosimilar portfolio commercialization, and biologic CMO growth.